BioCentury | Sep 14, 2018
Company News

Centre for the Commercialization of Antibiotics and Biologics and ImmunoBiochem partner for TNBC

...Centre for the Commercialization of Antibodies and Biologics (Toronto, Ontario) provided an undisclosed sum to ImmunoBiochem Corp....
...part of its new business strategy, which aims to create life science companies in Canada. ImmunoBiochem...
...Centre for the Commercialization of Antibiotics and Biologics, Toronto, Ontario ImmunoBiochem Corp., Toronto, Ontario Business: Cancer Shannon Lehnbeuter ImmunoBiochem Corp. Center...
BioCentury | Feb 9, 2018
Company News

Advanced Proteome, ImmunoBiochem to develop ADCs for TNBC

...Therapeutics Corp. (TSX-V:APC; FSE:0E8) and ImmunoBiochem Corp. (Toronto, Ontario) will evaluate combining an undisclosed antibody from ImmunoBiochem...
...Proteome's site-selective conjugation technology to develop antibody-drug conjugates (ADCs) to treat triple-negative breast cancer (TNBC). ImmunoBiochem...
...Proteome Therapeutics Corp. (TSX-V:APC; FSE:0E8), Boston, Mass. ImmunoBiochem Corp., Toronto, Ontario Business: Cancer Shannon Lehnbeuter Advanced Proteome Therapeutics Corp. ImmunoBiochem Corp....
Items per page:
1 - 2 of 2
BioCentury | Sep 14, 2018
Company News

Centre for the Commercialization of Antibiotics and Biologics and ImmunoBiochem partner for TNBC

...Centre for the Commercialization of Antibodies and Biologics (Toronto, Ontario) provided an undisclosed sum to ImmunoBiochem Corp....
...part of its new business strategy, which aims to create life science companies in Canada. ImmunoBiochem...
...Centre for the Commercialization of Antibiotics and Biologics, Toronto, Ontario ImmunoBiochem Corp., Toronto, Ontario Business: Cancer Shannon Lehnbeuter ImmunoBiochem Corp. Center...
BioCentury | Feb 9, 2018
Company News

Advanced Proteome, ImmunoBiochem to develop ADCs for TNBC

...Therapeutics Corp. (TSX-V:APC; FSE:0E8) and ImmunoBiochem Corp. (Toronto, Ontario) will evaluate combining an undisclosed antibody from ImmunoBiochem...
...Proteome's site-selective conjugation technology to develop antibody-drug conjugates (ADCs) to treat triple-negative breast cancer (TNBC). ImmunoBiochem...
...Proteome Therapeutics Corp. (TSX-V:APC; FSE:0E8), Boston, Mass. ImmunoBiochem Corp., Toronto, Ontario Business: Cancer Shannon Lehnbeuter Advanced Proteome Therapeutics Corp. ImmunoBiochem Corp....
Items per page:
1 - 2 of 2